Stockreport

Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update [Yahoo! Finance]

Tvardi Therapeutics, Inc.  (TVRD) 
PDF Topline data from Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) are anticipated in H2 2026 Cash runway expected to be sufficient to fund operations into [Read more]